RxDoctor Payments Data

Sally de Castro Tilsen

Physician Assistant · Newport Beach, CANPI 1023282019

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (51.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 63.0% of it on its own, with 54 other manufacturers making up the rest. Reporting peaked in 2021 at $21,795 and has fallen 62.5% since, to $8,166 in 2025. Among physician assistant clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$76,693in general payments, 2019–2025

Across 1,436 payments — averaging $53.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$48K
  • UCB, Inc.$4K
  • Teva Pharmaceuticals USA, Inc.$4K
  • Neurocrine Biosciences, Inc.$2K
  • Axsome Therapeutics, Inc.$2K
  • Lilly USA, LLC$2K
  • plus $15K from 49 others

What the payments were for

  • Speaking & faculty fees$39,49351%
  • Travel & lodging$9711%
  • Food & beverage$35,96547%
  • Education$2640%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)392$48,335
UCB, Inc.137$4,188
Teva Pharmaceuticals USA, Inc.138$3,822
Neurocrine Biosciences, Inc.86$2,239
Axsome Therapeutics, Inc.69$1,741
Lilly USA, LLC48$1,530
Pfizer79$1,522
Amgen(2 entities)42$1,451
AstraZeneca(2 entities)40$1,222
Lundbeck LLC25$952
Livanova USA, Inc.22$833
Upsher-smith Laboratories LLC37$660
Biohaven Pharmaceutical Holding Company Ltd.37$653
Eisai Inc.18$622
Amneal Pharmaceuticals LLC13$520
Biohaven Pharmaceuticals, Inc.27$498
Collegium Pharmaceutical, Inc.27$475
Johnson & Johnson(2 entities)16$452
Idorsia Pharmaceuticals US Inc14$427
SK Life Science, Inc.17$398
Alnylam Pharmaceuticals Inc.10$327
Impel Pharmaceuticals Inc.9$287
Tonix Medicines, Inc.16$268
Avadel CNS Pharmaceuticals, LLC2$245
Alkermes, Inc.2$242
Scilex Pharmaceuticals Inc.12$225
Abbott2$223
Tanabe Pharma America, Inc.9$213
EMD Serono, Inc.2$157
Jazz Pharmaceuticals Inc.4$155
Kyowa Kirin, Inc.2$143
Azurity Pharmaceuticals, Inc.8$132
Almatica Pharma LLC7$131
Avanir Pharmaceuticals, Inc.5$119
Takeda Pharmaceuticals U.S.A., Inc.6$112
Impel Pharmaceuticals LLC5$111
Supernus Pharmaceuticals, Inc.6$107
Biogen4$104
Merck6$102
Arbor Pharmaceuticals, Inc.5$78
Acadia Pharmaceuticals Inc3$75
Currax Pharmaceuticals LLC5$72
Harmony Biosciences LLC1$65
Valinor Pharma, LLC3$58
Bausch Health US, LLC3$55
Vertex2$51
Forte Bio-pharma LLC2$49
Argenx US, Inc.2$49
Otsuka America Pharmaceutical, Inc.2$36
Genentech USA, Inc.1$30
Averitas Pharma Inc.1$30
Endo Pharmaceuticals Inc.2$28
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$25
Redhill Biopharma Inc.1$24
Alfasigma USA, Inc.1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,693 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$289,132
Medicare patients
204
Services billed
37,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RizatriptanRizatriptan Benzoate27$614
Gabapentin28$520
Topiramate24$370
Duloxetine Hcl20$279
Sumatriptan Succinate27$233
Azithromycin11$51
Ondansetron OdtOndansetron13$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Upsher-smith Laboratories LLCTopiramate$660$37024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →